Viking Therapeutics has divulged dual agonists of GLP-1 and glucose-dependent insulinotropic receptor (GDIR) reported to be useful for the treatment of nonalcoholic fatty liver disease (NAFLD).

Baylor College of Medicine has disclosed bromodomain testis-specific protein (BD2 domain) (BRDT-BD2) inhibitors reported to be useful for the treatment of male contraception and male infertility.

Scripps Research Institute has synthesized dipeptidyl peptidase 4 (DPP4) inhibitors reported to be useful for the treatment of lung diseases.

Athos Therapeutics has patented pantetheinase (VNN1) inhibitors reported to be useful for the treatment of cancer and inflammation.

Halia Therapeutics has presented serine/threonine-protein kinase Nek7 inhibitors reported to be useful for the treatment of cancer, asthma, obesity, type 2 diabetes, hepatitis, peritonitis, neurodegeneration and psoriasis, among others.

HiberCell has described eukaryotic translation initiation factor 2-alpha kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and spinocerebellar ataxia.

Brii Biosciences has disclosed prodrugs of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) reported to be useful for the treatment of HIV infection.

Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) has patented thiazolopyrimidones acting as discoidin domain-containing receptor 1 (DDR1) and/or DDR2 inhibitors reported to be useful for the treatment of atherosclerosis, cancer, cirrhosis, hepatic fibrosis, pulmonary fibrosis, lupus nephritis, osteoarthritis and rheumatoid arthritis, among others.

Ascentage Pharma has divulged spirocyclic indenes acting as GTPase KRAS (Gly12Cys mutant) inhibitors reported to be useful for the treatment of cancer.

Sunshine Lake Pharma has synthesized amide pyrrole compounds reported to be useful for the treatment of liver cancer, cirrhosis and hepatitis B virus (HBV) infection.